Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $675.63 million. The enterprise value is $639.64 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 55.43 million shares outstanding. The number of shares has increased by 7.76% in one year.
| Current Share Class | 43.82M |
| Shares Outstanding | 55.43M |
| Shares Change (YoY) | +7.76% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 17.39% |
| Owned by Institutions (%) | 61.84% |
| Float | 38.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.97 |
| Forward PS | 3.88 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.41, with a Debt / Equity ratio of 0.70.
| Current Ratio | 5.41 |
| Quick Ratio | 5.14 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,135.87 |
Financial Efficiency
Return on equity (ROE) is -43.59% and return on invested capital (ROIC) is -15.83%.
| Return on Equity (ROE) | -43.59% |
| Return on Assets (ROA) | -12.90% |
| Return on Invested Capital (ROIC) | -15.83% |
| Return on Capital Employed (ROCE) | -25.99% |
| Revenue Per Employee | $276,757 |
| Profits Per Employee | -$377,930 |
| Employee Count | 834 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -895,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.40% in the last 52 weeks. The beta is 1.55, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | +47.40% |
| 50-Day Moving Average | 12.69 |
| 200-Day Moving Average | 10.40 |
| Relative Strength Index (RSI) | 43.36 |
| Average Volume (20 Days) | 1,594,126 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DNA had revenue of $230.82 million and -$315.19 million in losses. Loss per share was -$5.86.
| Revenue | 230.82M |
| Gross Profit | 182.32M |
| Operating Income | -294.77M |
| Pretax Income | -316.09M |
| Net Income | -315.19M |
| EBITDA | -230.79M |
| EBIT | -294.77M |
| Loss Per Share | -$5.86 |
Full Income StatementBalance Sheet
The company has $473.69 million in cash and $428.83 million in debt, giving a net cash position of $44.86 million or $0.81 per share.
| Cash & Cash Equivalents | 473.69M |
| Total Debt | 428.83M |
| Net Cash | 44.86M |
| Net Cash Per Share | $0.81 |
| Equity (Book Value) | 612.95M |
| Book Value Per Share | 11.06 |
| Working Capital | 426.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$237.71 million and capital expenditures -$36.46 million, giving a free cash flow of -$274.17 million.
| Operating Cash Flow | -237.71M |
| Capital Expenditures | -36.46M |
| Free Cash Flow | -274.17M |
| FCF Per Share | -$4.95 |
Full Cash Flow StatementMargins
Gross margin is 78.99%, with operating and profit margins of -127.71% and -136.56%.
| Gross Margin | 78.99% |
| Operating Margin | -127.71% |
| Pretax Margin | -136.94% |
| Profit Margin | -136.56% |
| EBITDA Margin | -99.99% |
| EBIT Margin | -127.71% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.76% |
| Shareholder Yield | -7.76% |
| Earnings Yield | -46.05% |
| FCF Yield | -40.05% |
Dividend DetailsAnalyst Forecast
The average price target for DNA is $9.00, which is -26.17% lower than the current price. The consensus rating is "Strong Sell".
| Price Target | $9.00 |
| Price Target Difference | -26.17% |
| Analyst Consensus | Strong Sell |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -6.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.51 |
| Piotroski F-Score | 3 |
